ArticleInternational journal of ophthalmology2025
Promotion of human choroidal melanoma cell metastases by FOXP3
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the role of Forkhead box protein P3 (FOXP3) in choroidal melanoma (CM) metastases and elucidate its underlying mechanisms.
methodsFOXP3 protein expression was analyzed in CM clinical specimens and cell lines. A stable FOXP3 knockout cell line and a transient FOXP3-overexpressing cell line were established, with transfection efficiencies confirmed by Western blotting (WB). Functional assays, including monoclonal formation, cell counting kit-8 (CCK-8) proliferation, migration, invasion, and
resultsFOXP3 expression was significantly elevated in both CM clinical specimens and cell lines. Functional analyses revealed that FOXP3 enhanced CM cell proliferation, migration, and invasion
conclusionThis study identifies FOXP3 as an oncogenic driver in CM, promoting tumor progression through the Wnt5a/CaMKII signaling pathway. These findings provide new insights into the molecular mechanisms of CM pathogenesis and highlight FOXP3 as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.